Member Info for TWatcher

A takeover would be purely for the manufacturing capability. Given that Mologic/GAD/Abingdon have plans in place for such expansion, it might be more likely to be a development company that wants to get into manufacturing ?

it appears more and more have little to add to the story, and have decided to just waste time bullying those that are actually contributing to the wider discussion. And yet these folks consider themselves investors..wierd.

some people get up at sunrise, rather that let the day go by. not sure why posting a previously unposted link that gives more information regarding Mologic's association with the Radx program isn't welcome, but I guess some people are a bit weird.

mologic is 1 of 7 LFTs that are at phase 2 under the radx program, that can be seen here (under POC):-
https://www.nibib.nih.gov/covid-19/radx-tech-program/radx-tech-phase2-awards

although an estimated budget of $11.7M is mentioned on the mologic tile, if you click view details you'll see that none has been award. This is the same as 2 others out of the 7. The remaining 4 have had their budgets assigned.

Certainly no different since Jan, as can be seen in the most recent archive version of the page dated the 15th of Jan here:-
(as its being extracted from the archive it takes a few seconds to load)
http://web.archive.org/web/20210122184453/https://www.omegadiagnostics.com/Investor-Relations/Share-Holder-Information

mologic, as an entirely private company can decide to be ethical and not make much profit. ODX has shareholders and needs to maximise profit from its capacity when it actually starts manufacturing. running lines at just a little profit was not envisaged by any shareholders. At a time were demand for LFTs is supposed to go thru the roof, it would be better to TT an LFT that customers actually want to pay money for, than continue with an poundland product.

20 posts on ODX in a year, and a look at them shows not one original thought on the company, nor one piece of research. He does do a good line in snark, so I guess that's his lot in life.

"Twatcher. Worse case scenario omega would manufacture moligics tests to fill capacity for low income countries. Even making 10p per test justifies the current mkt cap inmv ."

That's a hell of a come down from £2.50 that many on here were doing their forward looking year financials on, and around 1/10th of what they were making on the rtc test.

Gold standard to poundland, until they are in a position to produce the uk gov test. I'm hearing folks talk about end of Q2 for an avacta test. Should that be the test, then CK will have been correct and TT will happen before christmas.

"heres a really cheap test, wasn't good enough for uk gov, but hey you 3rd world guys will take anything, no no, dont go buying those other 20 tests that have been proved accurate and useful by porton down"

TT goes from week 20 to week 21. No Porton down validation for a test that's been CE since 2020. Abingdon. a publicly listed company has not announced any orders for the antibody LFT test, of which ODX could make 25%.

"In April we will deliver 2M tests per week."

Maybe ODX is starting a courier service as there is more and more evidence that they CAN'T have any antigen LFT orders, aren't stockpiling any antigen orders, and have no antibody orders.

ODX's entire lft output is totally out of their control, uk gov controls antigen, Abingdon sales force controls antibody. The one thing they can produce, the tri-antibody visitect test, has been available for order since oct. no body wants it.

And there was all these people talking about NDAs and stockpiling.
"They can't make anything in advance for the uk government"

If the mologic test fails (or has already failed) validation, we might never get to hear about it. The numbers from the uk gov report released on wed suggests that many tests fail validation. 'pause' is probably a nice way of a company getting out of failing...hold on just stop that validation process....

Mologic is a private company and therefore is under no obligation to release news that affects its fortunes, and in that situation, what private company would voluntarily release a PR that contains negative news? If Mologic doesn't announce, then ODX won't be able to. When ODX agreed the TT they did not publicly tie the test to UK validation, so they have no obligation to inform shareholders, and anyhow it is not their test and so can not announce independently as the LFT under validation is owned by mologic , not the ODX visitect one (even though they are generically the same).

Could be that all we will hear is that some other test is selected for the uk gov, and in the visitect test, ODX is left with a test that is identical to one that failed validation, which makes it quite a difficult sell to put it mildly.

If there is no news regarding validation/ uk gov selection of the mologic test very shortly, i.e. a week or two, there comes a point that it is reasonable to assume its failed validation. Otherwise how long do you wait, another month, another 6 months ?

you said the posts were misleading, not that you disagreed with how information was interpreted. So what was the misleading parts ?

Davde, what was the misleading bit again ?

"how many of the 17 tests are later flow"

Looks like you didn't even read the title of one of the most important docs for ODX released recently from uk gov. The answers to your questions are in the body of the link below without even going to the page. All are lateral flow tests. All are Rapid.

https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/outcome-of-the-evaluation-of-rapid-diagnostic-assays-for-specific-sars-cov-2-antigens-lateral-flow-devices

And counting the tests again, there are actually 19 tests there that potential customers can pick from.

I detect a collective confused

In the scenario whereby Mologic test has been deemed not good enough to get phase3a validation (never mind then selected as a gov test), and there are 17 tests that uk gov have passed phase3a validation, most people looking for a good test will check out the 17 tests firsts.

and you think buyers will be bashing the doors down for the visitect test, should it happen that it was supplied to Porton down for validation, but they decided it was not fit for validation, and buy none other than the uk gov !

I said a while back that everything now hangs on the mologic test being selected as a government test. Taking the fact that GAD has not mentioned getting any purchase orders from uk gov(test has been availabe for along time from GAD), along with the Mologic test conspicuous by its absence on the validated list update yesterday, it is looking more worrying.

bedhead, you mind is playing tricks on you, so determined is it not to see what is in front of it.

I didn't type "your visitect", I typed "the visitect"

maybe because of the rather important point that the £374M contract needs a test that has been validated by porton down.

My gawd, those are some rose tinted specs you have there if you won't be concern if an lft everyone has been waiting on is determined to be not good enough

what to debate the issues ?

The following doc also update yesterday, gives an overview of the evaluation stage of all tests.

https://www.gov.uk/government/publications/assessment-and-procurement-of-coronavirus-covid-19-tests/coronavirus-covid-19-serology-and-viral-detection-testing-uk-procurement-overview

Indicates that out of 102 validations that have been concluded or paused, only 17 have been validated. So thats 85 either failed or paused. 4 are currently being evaluated or validated, and another 15 are in early stages.

So 85 failed or paused
4 currently being evaluated
15 early stages.

given how long the mologic test has been around, it can hardly be in early stages. We know that its not passed evaluation. So that leaves it in the 85 that are failed or paused, or 4 that are being evaluated. The odds don't look great.